Standout Papers

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer 2018 2026 2020 2023 2.9k
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer (2018)
    Peter Schmid, Sylvia Adams et al. New England Journal of Medicine
  2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
    Peter Schmid, Hope S. Rugo et al. The Lancet Oncology
  3. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer (2018)
    Leisha A. Emens, Cristina Cruz et al. JAMA Oncology
  4. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer (2022)
    Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine
  5. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study (2018)
    Sylvia Adams, Sherene Loi et al. Annals of Oncology
  6. Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer (2018)
    Tiffany A. Traina, Kathy D. Miller et al. Journal of Clinical Oncology
  7. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial (2021)
    Eric P. Winer, Seock‐Ah Im et al. The Lancet Oncology
  8. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021)
    Leisha A. Emens, Luciana Molinero et al. JNCI Journal of the National Cancer Institute
  9. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors (2021)
    Gerald S. Falchook, Jeffrey R. Infante et al. EClinicalMedicine
  10. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 (2024)
    Lajos Pusztai, Carsten Denkert et al. Annals of Oncology

Immediate Impact

2 by Nobel laureates 18 from Science/Nature 68 standout
Sub-graph 1 of 21

Citing Papers

Pyridinium Rotor Strategy toward a Robust Photothermal Agent for STING Activation and Multimodal Image-Guided Immunotherapy for Triple-Negative Breast Cancer
2025 Standout
Natural killer cell therapies
2024 StandoutNature
1 intermediate paper

Works of Peter Schmid being referenced

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout

Author Peers

Author Last Decade Papers Cites
Peter Schmid 8002 3424 3134 203 10.6k
Justin M. Balko 5880 2172 2453 146 11.0k
Leisha A. Emens 10452 3058 2517 166 14.1k
Anthony Gonçalvès 5977 2884 2232 316 9.2k
Scott Gettinger 9980 6665 1688 255 12.8k
Luciana Molinero 6401 2140 2072 101 8.9k
Joseph P. Eder 8093 3137 1596 176 12.0k
Naiyer A. Rizvi 10797 7606 2182 274 14.6k
Rebecca Dent 6229 2353 3939 183 9.8k
John A. Thompson 5591 4265 2126 122 11.0k
Eliezer M. Van Allen 4619 3739 3135 227 10.9k

All Works

Loading papers...

Rankless by CCL
2026